Stroke was the highest cause of death and disability of all ages (15.4%) in Indonesia based on RISKESDAS 2007. Thrombotic strokeis one of ischemic stroke that had prevalence of 58.3%. Acetosal/ASA is one of anti-platelet which has been used widely as secondaryprevention for stroke meanwhile, diabetic melitus (DM) was one of the risk factor. Anti-aggregation platelet effect was measured byLight Transmission Aggregometry (LTA). The test had been done twice, before and after ASA usage for 7-10 days. 24 patients thatwere involved, hospitalized for acute thrombotic stroke at least 7-10 days, 15 from non-diabetic group and 9 from diabetic group.The results showed that there is no significant difference in demographic and risk factors for those patients (X2 test, p>0.05). Theaggregation percentage were analyzed statistically by pair t-test for pre-and post-within group, and independent t-test to comparethose two groups. The aggregation percentage of diabetic patients (n=9) was 11-48% (pre) and 7-43% (post). Meanwhile, theaggregation percentage of non-diabetic patients (n=15) was 13-64% (pre) and 13-39% (post). The usage of ASA 1 x 100 mg gave alowering aggregation percentage (t 0,05). It can be concluded that there were no difference on anti-platelet aggregation of ASAbetween diabetic and non diabetic patients with acute thrombotic stroke. For practical purpose, it can be suggested to confirmpercentage aggregation ASA with instrument that applied reliable clinical meaning.(FMI 2013;49 163-167)
Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.